Increased expression of programmed cell death 1 (PD-L1, also known as CD274) has previously been reported in HCC treated with sorafenib (El Dika et al., 2019), indicating that CD274 expression can effectively assess the therapeutic effect of HCC during the treatment of HCC. Here, CD274 is linked to hepatocellular carcinoma.